What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO)

IF 4.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Martha Hickey , Alison H. Trainer , Efrosinia O. Krejany , Alison Brand , Susan M. Domchek , Vanessa Pac Soo , Sabine Braat , Gita D. Mishra
{"title":"What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO)","authors":"Martha Hickey ,&nbsp;Alison H. Trainer ,&nbsp;Efrosinia O. Krejany ,&nbsp;Alison Brand ,&nbsp;Susan M. Domchek ,&nbsp;Vanessa Pac Soo ,&nbsp;Sabine Braat ,&nbsp;Gita D. Mishra","doi":"10.1016/j.ygyno.2024.10.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To measure vasomotor symptoms and menopause-related quality of life up to 24 months after RRSO, and the effects of Menopausal Hormone Therapy (MHT).</div></div><div><h3>Methods</h3><div>Prospective observational study of 104 premenopausal women at elevated risk of ovarian cancer planning RRSO and age-matched comparators (<em>n</em> = 102) who retained their ovaries. Vasomotor symptoms and quality of life were measured using the Menopause-specific QoL Intervention (MENQOL-I) scale. Changes in QoL were examined using a population-averaged linear regression model. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12615000082505.</div></div><div><h3>Results</h3><div>At 24 months after RRSO the prevalence of vasomotor symptoms had increased from 6 % at baseline to 59 % and night sweats from 21 % to 39 %. There was a clinically and statistically significant difference of 1.14 points in MENQOL score (95 % CI 0.71, 1.57, <em>p</em> &lt; 0.001) in the change from baseline to 24 months in vasomotor symptoms between the RRSO vs comparison group. Following RRSO, 61 % started MHT, most (79 %) within 3 months. At 24 months, 54 % of MHT users reported vasomotor symptoms of which around half (52 %) categorized these as “mild”. Amongst non-MHT users, 88 % reported vasomotor symptoms at 24 months of which 72 % categorized these as “mild”. Menopause-related QoL decreased after RRSO but was stable in comparators. Menopause related quality of life was higher in MHT users vs non-users.</div></div><div><h3>Conclusions</h3><div>Vasomotor symptoms peak by 3 months after RRSO and are stable over 24 months. MHT mitigates but does not fully resolve vasomotor symptoms and improves menopause-related QoL.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"191 ","pages":"Pages 201-211"},"PeriodicalIF":4.5000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090825824011570","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To measure vasomotor symptoms and menopause-related quality of life up to 24 months after RRSO, and the effects of Menopausal Hormone Therapy (MHT).

Methods

Prospective observational study of 104 premenopausal women at elevated risk of ovarian cancer planning RRSO and age-matched comparators (n = 102) who retained their ovaries. Vasomotor symptoms and quality of life were measured using the Menopause-specific QoL Intervention (MENQOL-I) scale. Changes in QoL were examined using a population-averaged linear regression model. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12615000082505.

Results

At 24 months after RRSO the prevalence of vasomotor symptoms had increased from 6 % at baseline to 59 % and night sweats from 21 % to 39 %. There was a clinically and statistically significant difference of 1.14 points in MENQOL score (95 % CI 0.71, 1.57, p < 0.001) in the change from baseline to 24 months in vasomotor symptoms between the RRSO vs comparison group. Following RRSO, 61 % started MHT, most (79 %) within 3 months. At 24 months, 54 % of MHT users reported vasomotor symptoms of which around half (52 %) categorized these as “mild”. Amongst non-MHT users, 88 % reported vasomotor symptoms at 24 months of which 72 % categorized these as “mild”. Menopause-related QoL decreased after RRSO but was stable in comparators. Menopause related quality of life was higher in MHT users vs non-users.

Conclusions

Vasomotor symptoms peak by 3 months after RRSO and are stable over 24 months. MHT mitigates but does not fully resolve vasomotor symptoms and improves menopause-related QoL.
更年期之后会发生什么?(WHAM):绝经前风险降低性输卵管切除术(RRSO)24 个月后血管运动症状和绝经相关生活质量的前瞻性对照研究。
目的:测量RRSO后24个月内的血管运动症状和与绝经相关的生活质量:测量RRSO后24个月内的血管运动症状和更年期相关生活质量,以及更年期激素疗法(MHT)的效果:前瞻性观察研究:104 名卵巢癌风险较高的绝经前妇女计划进行 RRSO,年龄匹配的比较者(n = 102)保留了卵巢。血管运动症状和生活质量采用更年期特异性 QoL 干预(MENQOL-I)量表进行测量。使用人群平均线性回归模型对 QoL 的变化进行了检验。该研究已在澳大利亚和新西兰临床试验注册中心(ACTRN12615000082505)注册:在 RRSO 治疗 24 个月后,血管运动症状的发生率从基线时的 6% 增加到 59%,盗汗率从 21% 增加到 39%。MENQOL 评分有 1.14 分的临床和统计学显著差异(95 % CI 0.71, 1.57, p 结论):血管运动症状在 RRSO 后 3 个月达到高峰,并在 24 个月内保持稳定。MHT 可减轻但不能完全缓解血管运动症状,并可改善与更年期相关的 QoL。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gynecologic oncology
Gynecologic oncology 医学-妇产科学
CiteScore
8.60
自引率
6.40%
发文量
1062
审稿时长
37 days
期刊介绍: Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信